Hypertension in Cushing's syndrome: From pathogenesis to treatment

Neuroendocrinology

Volumn 92, Issue SUPPL. 1, 2010, Pages 44-49

  Cicala, Maria Verena ^a   Mantero, Franco ^a,b  

^a UNIVERSITY OF PADOVA   (Italy)

^b UNIVERSITY OF PADUA MEDICAL SCHOOL   (Italy)

Author keywords

Cushing's syndrome; Multiple therapy; Resistant hypertension

Indexed keywords

11BETA HYDROXYSTEROID DEHYDROGENASE; ALDOSTERONE; ANGIOTENSIN; ANGIOTENSIN II; BROMOCRIPTINE; CALCIUM CHANNEL BLOCKING AGENT; CANRENONE; CORTICOTROPIN; CORTISONE; CYPROHEPTADINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EPLERENONE; GLUCOCORTICOID RECEPTOR; HYDROCORTISONE; KALLIKREIN; KININ; MIFEPRISTONE; MINERALOCORTICOID RECEPTOR; NITRIC OXIDE SYNTHASE; OCTREOTIDE; PASIREOTIDE; PIOGLITAZONE; PROSTACYCLIN; RENIN; RITANSERIN; ROSIGLITAZONE; SARTAN DERIVATIVE; SPIRONOLACTONE; UNINDEXED DRUG; VALPROIC ACID;

ADRENALECTOMY; ADRENERGIC RECEPTOR BLOCKING; ANTIHYPERTENSIVE THERAPY; BLOOD PRESSURE REGULATION; BLOOD VESSEL REACTIVITY; CARDIOVASCULAR AUTOREGULATION; CLINICAL FEATURE; CONFERENCE PAPER; CUSHING SYNDROME; DIURETIC THERAPY; HUMAN; HYPERCORTISOLISM; HYPERTENSION; HYPOPHYSECTOMY; HYPOPHYSIS ADENOMA; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SLEEP APNEA SYNDROME;

ADULT; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CUSHING SYNDROME; HUMANS; HYPERTENSION; RENIN-ANGIOTENSIN SYSTEM;

EID: 77956517756     PISSN: 00283835     EISSN: None     Source Type: Journal    
DOI: 10.1159/000314315     Document Type: Conference Paper

References (19)

1. Magiakou MA, Smyrnaki P, Chrousos GP: Hypertension in Cushing's syndrome. Best Pract Res Clin Endocrinol Metab 2006; 20: 467-482.
2. Muiesan ML, Lupia M, Salvetti M, Grigolet-to C, Sonino N, Boscaro M, Rosei EA, Man-tero F, Fallo F: Left ventricular structural and functional characteristics in Cushing's syndrome. J Am Coll Cardiol 2003; 41:2275-2279.
3. Felix J, Frey A, Odermatt B, Frey M: Gluco-corticoid-mediated mineralocorticoid receptor activation and hypertension. Curr Opin Nephrol Hy pertens 2004; 13: 451-458.
4. Ferrari P, Bonny O: Forms of mineralocorti-coid hypertension. Vitam Horm 2003; 66: 113-156.
5. Ulick S, Chan CK, Gill JR Jr, Gutkin M, Letcher L, Mantero F, New MI: Defective fasciculata zone function as the mechanism of glucocorticoid- remediable aldosteronism. J Clin Endocrinal Metab 1990; 71: 1151-1157.
6. Quinkler M, Stewart PM: Hypertension and the cortisol-cortisone shuttle. J Clin Endo-crinol Metab 2003; 88:2384-2392.
7. Ferrari P, Krozowski Z: Role of the 11beta-hydroxysteroid dehydrogenase type 2 in blood pressure regulation. Kidney Int 2000; 57: 1374-1381.
8. Baid S, Nieman LK: Glucocorticoid excess and hypertension. Curr Hypertens Rep 2004; 6:493-499.
9. Scheuer DA, Becht AG: Glucocorticoids potentiate central actions of angiotensin to increase arterial pressure. Am J Physiol Regul Integr Comp Physiol 2001; 280:1719-1726.
10. Kiri lov G, Tomova A, Dakovsk a L, Kumanov P, Shinkov A, Alexandrov AS: Elevated plasma endot helin as an additiona l cardiovascular risk factor in patients with Cushing's syndrome. Eur J Endocrinol 2003; 14 9: 549-553.
11. Mangos GJ, Whitworth JA, Williamson PM: Glucocorticoids and the kidney. Nephrology 2003; 8: 267-273.
12. McFarlane SI, Banerji M, Sowers JR: Insulin resistance and cardiovascular disease. J Clin Endocrinol Metab 2001; 86:713-718.
13. Sacerdote A, Weiss K, Tran T, Rokeya Noor B, McFarlane SI: Hypertension in patients with Cushing's disease: pathophysiology, diagnosis, and management. Curr Hypertens Rep 2005; 7:212-218.
14. Bernini G, Moretti A, Iacconi A, et al: An-thropometric, hemodynamic, humoral, and hormonal evaluation in patients with incidental adrenocortical adenomas before and after surgery. Eur J Endocrinol 2003; 148: 213-219.
15. Lodish MB, Sinaii N, Patronas N, Batista DL, Keil M, Samuel J, Moran J, Verma S, Popov ic J, Stratakis CA: Blood pressure in pediatric patients with Cushing syndrome. J Clin En-docrinol Metab 2009; 94: 2002-2008.
16. Morris D, Grossman A: The medical management of Cushing's syndrome. Ann NY Acad Sci 2002; 970:119-133.
17. El-Atat FA, Nicasio J, Clark LT, et al: An overview of the beneficial cardiovascular effects of thiazolidinediones. Therapy 2005; 2: 113e-119e.
18. Rossi GP: Losartan metabolite EXP3179: an AT1-receptor-independent treatment strategy for patients with the metabolic syndrome? Hyper tension 2009; 54: 710-712.
19. Mancini T, Kola B, Mantero F, Boscaro M, Arnaldi G: High cardiovascular risk in patients with Cushing's syndrome according to 1999 WHO/ISH guidelines. Clin Endocrinol 2004; 61:768-777.